Income Statement

Orion's revenue growth in the last quarter has been driven by the strong performance of its Innovative Medicines segment, which has seen significant increases in sales and royalties. This growth can be attributed to the company's strategic focus on developing and commercializing innovative products, as well as its ability to navigate the complexities of the pharmaceutical market. The segment's success has been further bolstered by the strong performance of its Branded Products and Fermion divisions, which have also seen significant growth. Looking ahead, Orion's revenue is expected to continue its upward trend, driven by the company's pipeline of new products and its expanding presence in key markets. However, the company's revenue growth may be impacted by exchange rate fluctuations, which have had a negative impact on its net sales in the past.

The realised revenue for Q2 2026 is 521.6 million Euros, while the predicted revenue for Q2 2027 (e) is 551.0 million Euros. The revenue is expected to increase by 29.4 million Euros, which is a 5.6% increase from the realised value. The revenue is expected to increase by 88.2 million Euros from 2025 to 2026, which is a 4.7% change. From 2026 to 2027, the revenue is predicted to increase by 201.1 million Euros, representing a 10.2% change. The annual revenue values for the respective years are 1889.6 million Euros, 1977.8 million Euros, and 2078.9 million Euros.

Orion's EBIT profitability has demonstrated a significant improvement, driven primarily by the company's ability to effectively manage its operating expenses. The reduction in operating expenses, coupled with a notable increase in sales and royalties, has contributed to the enhanced profitability. Furthermore, the company's strategic investments in research and development have begun to yield returns, as evidenced by the growth in operating profit. However, it is essential to note that the increase in operating expenses, particularly in research and development costs, has also played a role in the improved EBIT profitability. Overall, Orion's EBIT profitability has shown a substantial improvement, reflecting the company's efforts to optimize its operations and capitalize on emerging opportunities.

The realised Ebit for Q2 2026 is 176.6 million Euros, while the predicted Ebit for Q2 2027 (e) is 164.7 million Euros. The expected change in Ebit from Q2 2026 to Q2 2027 (e) is a decrease of 12.9 million Euros, which represents a percentage decrease of approximately 7.3%. The expected change in Ebit from 2025 to 2026 is a decrease of 35.3 million Euros, which translates to a percentage decrease of 5.6%. From 2026 to 2027, the expected change is a decrease of 70.5 million Euros, representing a percentage decrease of 11.8%. The annual Ebit values are 631.6 million Euros in 2025, 596.3 million Euros in 2026, and 525.8 million Euros in 2027.

The realised value for Q2 2026 is 175.8 million Euros, while the predicted value for Q2 2027 (e) is 164.7 million Euros. The expected change in one year is a decrease of 11.1 million Euros, which translates to a percentage decrease of approximately 6.3%. The change in Profit before tax from 2025 to 2026 is a decrease of 33.5 million Euros, which is a 5.3% drop. From 2026 to 2027, the change is a decrease of 68.3 million Euros, which is a 11.5% drop. The annual values for Profit before tax are 627.6 million Euros in 2025, 594.1 million Euros in 2026, and 525.8 million Euros in 2027.

The realised value for Q2 2026 is 140.2 million Euros, and the predicted value for Q2 2027 (e) is 131.8 million Euros. The expected change in profit from Q2 2026 to Q2 2027 (e) is a decrease of 8.4 million Euros, which translates to a percentage decrease of approximately 6%. The change in profit from 2025 to 2026 is a decrease of 41.3 million Euros, which is a 7.9% drop. The change in profit from 2026 to 2027 is a decrease of 54.8 million Euros, which is a 11.5% drop. The annual profit values are 515.8 million Euros in 2025, 474.5 million Euros in 2026, and 420.7 million Euros in 2027.